Claudio Laudani/X
Nov 18, 2025, 15:08
Claudio Laudani: DOACs Have Transformed the Landscape of Anticoagulation
Claudio Laudani, Cardiovascular Disease Fellow UNICT, Post-Doc Research Scholar UFHealth JAX, shared on LinkedIn:
”Direct oral anticoagulants (DOACs) have transformed the landscape of anticoagulation, offering more predictable pharmacology, improved safety, and easier management compared to vitamin K antagonists.
In this comprehensive review, we examine:
- Pharmacokinetic and pharmacodynamic profiles of apixaban, rivaroxaban, dabigatran, and edoxaban.
- Evidence supporting their use across atrial fibrillation, venous thromboembolism, cancer-associated thrombosis, and atherosclerosis compared with other antithrombotic strategies.
- How to optimize DOAC therapy in vulnerable scenarios (renal impairment, elderly patients, perioperative management).
- Remaining gaps and unmet clinical needs where further research is required, such as patients with rheumatic heart disease, mechanical heart valves, antiphospholipid syndrome, and patients with LVAD.”
Read the full article here.
Article: Safety and optimal use of direct oral anticoagulant therapy
Authors: Claudio Laudani, Luis Ortega-Paz, Ali Zgheib, Georges El Khoury, Mohmmad Alawajneh, Maryam Farahmandsadr, Davide Capodanno, Dominick J Angiolillo
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Apr 6, 2026, 16:39Dhinesh Selvaraju: FDA Approves Narsoplimab (Yartemlea) as 1st Treatment for TA-TMA in Adults and Children
-
Apr 6, 2026, 16:38Linda Vorberg: A Detailed Analysis on The Usefulness of CT for DL-Based Stroke Lesion Segmentation
-
Apr 6, 2026, 16:37Colleen Hearn: Telestroke Helps Resource-Limited Facilities Gain Access to Unavailable Expertise
-
Apr 6, 2026, 16:37Nicolas Hubacz: AI Maps Neuroplasticity in Stroke Recovery – How the Brain Adapts After Injury
-
Apr 6, 2026, 16:36Cristina de Diego Alonso: Movement Is Not Just an Exercise, It Is The Rhythm of Daily Life
-
Apr 6, 2026, 16:35Charles Okyere Boadu: What Is The Most Likely Cause of Persistent Thrombocytopenia Despite Transfusion?
-
Apr 6, 2026, 16:34Tumor Mutations and VTE Risk – New Insights from a 12,500-Patient Cancer Study – JTH
-
Apr 6, 2026, 16:31Wolfgang Miesbach: New Real-World Data Reveal Ongoing Burden in Moderate-to-Severe Haemophilia A
-
Apr 6, 2026, 16:26Heghine Khachatryan։ Targeting High Risk Antiphospholipid Syndrome in Pregnancy with Hydroxychloroquine